Results 151 to 160 of about 39,316 (219)

Biomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy

Advanced Science, Volume 13, Issue 21, 13 April 2026.
Biomimetic MOF‐based drug delivery nanoplatforms synthesized using liposomes or cell membranes as camouflage for multiple cancer therapeutics. ABSTRACT The integration of metal‐organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine.
Qilu Wu, Jia Song Deon Chon, Yuxiao Feng, Kang Liang, Shiming Li, Can Yang Zhang, Jun Ge   +6 more
wiley   +1 more source

CircRSU1 Activates the hnRNPA1/HIF‐1α/CD24 Signaling Axis, Promoting Stemness Features of Hepatocellular Carcinoma

Advanced Science, Volume 13, Issue 22, 17 April 2026.
This study reveals circRSU1 with important oncogenic roles in hepatocellular carcinoma (HCC). CircRSU1, highly abundant in HCC, interacts with and stabilizes hnRNPA1 from ubiquitination and degradation. This stabilization facilitates hnRNPA1 binding to the internal ribosome entry site of HIF1A to increase HIF‐1α protein translation.
Shuting Xue, Danduo Wei, Yongzhi Zhao, Jinchang Pan, Hanyuan Zhang, Niya Liu, Jianjuan Zhang, Jiaxin Liu, Jianping Jin, Mu Xiao, Xinhua Feng, Aifu Lin, Lei Zhao, Stephanie Roessler, Junfang Ji   +14 more
wiley   +1 more source

PIK3CA Mutations Downregulate PPT1 to Promote Adipogenesis by Suppressing P300 Depalmitoylation and Phase Separation

Advanced Science, Volume 13, Issue 19, 2 April 2026.
This study demonstrates that somatic PIK3CA mutations suppress PPT1 expression via activation of the PI3K–AKT–c‐JUN axis. This reduction in PPT1 weakens its interaction with P300, thereby increasing palmitoylation at C1176 of P300 and protecting P300 from lysosomal degradation.
Hongrui Chen, Zening Huang, Rui Chang, Wei Gao, Yajing Qiu, Bin Sun, Chen Hua, Xiaoxi Lin   +7 more
wiley   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy

Cancer Innovation, Volume 5, Issue 2, April 2026.
Chimeric antigen receptor (CAR) T‐cell therapy, although revolutionary for haematological malignancies, faces significant challenges, including T‐cell exhaustion, limited persistence, and treatment‐related toxicity. The integration of small‐molecule compounds offers a promising strategy to overcome these limitations.
Rangzi Yi, Zijian Zhang, Yang Yang, Haichuan Zhu   +3 more
wiley   +1 more source

Lenalidomide Plus Dexamethasone as FIRST‐Line Therapy in Transplant‐Ineligible Patients With Multiple Myeloma: Final Results of the Prospective, Non‐Interventional Study FIRST‐NIS and Comparison With the FIRST Pivotal Phase III Clinical Trial

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Objectives Lenalidomide and low‐dose dexamethasone (Rd) is a standard regimen for transplant‐ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM), for whom a multi‐drug treatment regimen is not considered appropriate. While Rd has been intensively investigated in clinical trials, prospective real‐world data are still scarce ...
H. Nückel, T. Behlendorf, H. Schulz, M. Schulze, C. Schardt, T. Medinger, M. Koenigsmann, T. Dechow, M. Indorf, D. Bürkle, V. Engelbertz, J. Rauh, B. Schmidt, A. Sauer, C. Vannier, K. Potthoff   +15 more
wiley   +1 more source

Light Chain Deposition Disease With Trace Monoclonal Proteinemia as Severe Renal Failure: A Case Image

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT A 56‐year‐old woman with unexplained severe renal failure and negative initial monoclonal studies was diagnosed with LCDD only after renal biopsy.
Ling Qin, Hui Bao, Peiyong Wang, Yaxiang Song, Wen Xue   +4 more
wiley   +1 more source

Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody‐Positive Myasthenia Gravis

European Journal of Immunology, Volume 56, Issue 4, April 2026.
Current plasma cell–targeting therapies lack antigen specificity. Using an antibody‐mediated cytotoxicity engager (ACE) targeting the α‐subunit of the extracellular domain of the human acetylcholine receptor (hAChR αECD), we selectively depleted pathogenic antibody‐secreting cells in a myasthenia gravis model, reducing autoantibody titers and disease ...
Laleh Khodadadi, Deborah Puppe, Dilara S. Cirillo, Carolina Martinez‐Cingolani, Jens Klotsche, Andreas Pelz, Siegfried Kohler, Qingyu Cheng, Konstantinos Lazaridis, Michael Fichtner, Jan Pille, Andrey Kruglov, Marina Bondareva, Tobias Alexander, Andreas Radbruch, Andreas Meisel, Falk Hiepe   +16 more
wiley   +1 more source

Monocyte‐mediated metabolic rewiring via CD31‐CD38 interactions promotes growth and drug‐resistance in multiple myeloma

HemaSphere, Volume 10, Issue 4, April 2026.
Abstract Multiple myeloma (MM) cells interact with different components of the bone marrow (BM) microenvironment, which plays a critical role in MM progression and confers resistance to therapy. Here, we report that monocytes actively control MM cell metabolism by transferring mitochondria to MM cells, thereby increasing their mitochondrial content ...
Ramin Raoof, Giada Dal Collo, Helga Simon‐Molas, Panagiota Tzortzi, Konxhe Kulaj, Elif N. Demirez, Crescenzo Massaro, Renée Poels, Charlotte L. B. M. Korst, Chloe A. O'Neill, Wassilis S. C. Bruins, Marloes E. C. Broekmans, Payam Behradkia, Maria Krevvata, Sonja Zweegman, Arnon P. Kater, Serena R. Baglio, Tuna Mutis, Niels W. C. J. van de Donk   +18 more
wiley   +1 more source

LIN‐24 as a Molecular Switch: Dual Cytotoxic and Cytoprotective Roles of an Aerolysin‐Like Protein in C. elegans

Journal of Applied Toxicology, Volume 46, Issue 4, Page 1076-1082, April 2026.
ABSTRACT LIN‐24, an aerolysin‐like pore‐forming protein in Caenorhabditis elegans, exemplifies how ancient cytolytic mechanisms have evolved into regulated cellular processes. Initially identified for inducing nonapoptotic, engulfment‐dependent cell death in vulval precursor cells, LIN‐24 has emerged as a multifunctional regulator of metabolism, stress
Sharoen Yu Ming Lim
wiley   +1 more source